Company Overview - RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunological diseases [1][3] - The company utilizes a proprietary discovery and development platform to advance both biologics and selective small molecules aimed at normalizing critical immune drivers underlying these conditions [3] Upcoming Presentation - Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, at 9:00 a.m. Pacific Time [1]

Core Insights - RAPT Therapeutics, Inc. has appointed Lori Lyons-Williams as the new chair of its board of directors, succeeding William Rieflin, effective January 3, 2025 [1][2] - Lori Lyons-Williams brings over 20 years of experience in the pharmaceutical and biotech industries, currently serving as President and CEO of Abdera Therapeutics [2][3] - The company is focused on advancing its late-stage development and potential commercialization of therapies for inflammatory diseases, particularly RPT904 for food allergies and other allergic diseases [3] Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology-based therapies for inflammatory and immunological diseases [1][3] - The company utilizes a proprietary discovery and development platform to create both biologics and selective small molecules aimed at normalizing immune drivers related to these conditions [3]

JYB1904目前处于中国II期临床试验，针对哮喘和慢性自发性荨麻疹。 本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 据IPO早知道消息，12月23日，RAPT Therapeutics（RAPT.US，下称RAPT）宣布获上海济煜医 药科技有限公司（下称"济煜医药"）授权引进长效IgE抗体JYB1904（RPT904）的大中华区外全球 权益，济煜医药将获得3500万美元预付款，最高6.725亿美元里程碑付款及一定比例的销售分成， 交易总额7.075亿美元。 治疗选择。奥马珠单抗以被获批用于治疗哮喘、CSU、慢性鼻窦炎伴有鼻息肉（CRSwNP）及食物 过敏等过敏性疾病。 RAPT总裁兼首席执行官Brian Wong表示，奥马珠单抗在今年初获批后市场占有率快速扩大证明了 这一治疗领域有巨大需求。而RPT904有望成为这一领域的同类最佳产品。RAPT计划于2025年下 半年启动RPT904 在食物过敏中的IIb期临床研究。 同时，RAPT Therapeutics还于23日披露了1.5亿美元的私募配售计划， 由The Column Group和 TCGX领投 ，新老投资者共同参与，包括 ...

Core Viewpoint - RAPT Therapeutics, Inc. has announced a private placement of securities to raise approximately $150 million for research and development and general corporate purposes [1][2]. Group 1: Private Placement Details - The company will issue 100,000,000 shares of common stock at a price of $0.85 per share and pre-funded warrants to purchase up to 76,452,000 shares at a price of $0.8499 per warrant [1]. - The private placement is expected to close on or about December 27, 2024, subject to customary closing conditions [1]. - The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable [1]. Group 2: Use of Proceeds - Net proceeds from the private placement are intended to fund the research and development of the company's pipeline and for general corporate purposes [2]. Group 3: Company Overview - RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on developing therapies for inflammatory diseases with significant unmet needs [3]. - The company utilizes a proprietary discovery and development platform to advance both biologics and selective small molecules targeting critical immune drivers [3]. Group 4: Placement Agent and Investors - Leerink Partners is acting as the sole placement agent for the private placement [3]. - The placement was led by The Column Group and TCGX, with participation from various investors including BVF Partners LP, Deep Track Capital, and others [6].

Core Insights - RAPT Therapeutics has entered into an exclusive licensing agreement with Jemincare for the development and commercialization of RPT904, a novel anti-IgE monoclonal antibody, with worldwide rights excluding China [2][3] - Jemincare will receive a $35 million upfront payment, potential milestone payments up to $672.5 million, and royalties on future sales of RPT904 outside its territory [2][3] - RPT904 is being developed as a potentially improved treatment option for food allergies, targeting the same epitope as omalizumab but with an extended half-life [3][9] Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on immunology and developing therapies for inflammatory diseases with significant unmet needs [10] - Jemincare, a leading pharmaceutical company in China, specializes in the development and commercialization of therapeutics across various fields including oncology and respiratory diseases [11] Clinical Development - Jemincare has completed a Phase 1 study of JYB1904, demonstrating good safety and tolerability, with a median half-life more than twice that of omalizumab [4] - Jemincare is currently conducting two Phase 2 trials for JYB1904 in asthma and chronic spontaneous urticaria, with topline data expected in 2025 and 2026 respectively [5] - RAPT plans to initiate a Phase 2b clinical trial of RPT904 in food allergy in the second half of 2025 [3][8]

Financial Performance - Net loss for Q3 2024 was $18.4 million, a decrease of 41.4% compared to $31.4 million in Q3 2023[2] - Net loss for the nine months ended September 30, 2024, was $76.6 million, a reduction of 10.3% from $85.9 million for the same period in 2023[6] Research and Development Expenses - Research and development expenses for Q3 2024 were $13.3 million, down 50.7% from $27.0 million in Q3 2023[3] - Research and development expenses for the nine months ended September 30, 2024, totaled $60.8 million, down 18.1% from $74.2 million in the same period of 2023[7] General and Administrative Expenses - General and administrative expenses for Q3 2024 were $6.4 million, a slight decrease of 7.2% compared to $6.9 million in Q3 2023[4] - General and administrative expenses for the nine months ended September 30, 2024, increased to $20.9 million, up 6.7% from $19.6 million in the same period of 2023[8] Operating Expenses - Total operating expenses for Q3 2024 were $19.8 million, a decrease of 41.7% from $33.9 million in Q3 2023[11] Workforce Reduction - The company reduced its workforce by approximately 40%, affecting 47 employees, incurring $0.9 million in restructuring charges[5] Cash and Assets - As of September 30, 2024, the company had cash and cash equivalents and marketable securities totaling $97.9 million[8] - Total assets as of September 30, 2024, were $108.5 million, down from $173.3 million as of December 31, 2023[12]

How to Determine if a Stock is Oversold quest for reaching the old equilibrium of supply and demand. Rapt Therapeutics (RAPT) has been on a downward spiral lately with significant selling pressure. After declining 15.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. We use Relative Strength Index (RSI), one of th ...

Rapt Therapeutics (RAPT) has been beaten down lately with too much selling pressure. While the stock has lost 47.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillato ...

Shidlovski/iStock via Getty Images Thesis overview RAPT Therapeutics (NASDAQ:RAPT) is developing oral small molecule therapies for inflammation (atopic dermatitis and asthma) and oncology indications. The most advanced candidate is zelnecirnon (ZEL) currently in ph2 stage for the indications of atopic dermatitis (AD) and asthma, with promising phase 1 safety and efficacy results in AD. RAPT was trading at a market cap close to $900M up until recently, when RAPT announced an FDA clinical hold due to hepatic ...

Rapt Therapeutics (RAPT) has been beaten down lately with too much selling pressure. While the stock has lost 52.9% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscilla ...